Amgen (AMGN) closed at $465.45 on November 2, 2026, down 0.1% from the previous close, on volume of 2,553,810 shares (30-day average 2,742,029).
Data as of November 2, 2026.
2-Nov-2026
Options Volatility and Implied Earnings Moves Today, November 03, 2026
TipRanks (Tue, 3-Nov 7:06 AM ET)
Amgen Q3 preview: What to expect
Seeking Alpha News (Mon, 2-Nov 12:48 PM ET)
Amgen Advances Otezla Dosing Study as Investors Watch for a Simpler Formulation
TipRanks (Mon, 2-Nov 11:30 AM ET)
The Week That Was, The Week Ahead: Macro and Markets, November 1
TipRanks (Sun, 1-Nov 4:50 AM ET)
Healthcare Earnings Scoreboard: 96% beat EPS estimates, 70% post Y/Y earnings growth
Seeking Alpha News (Sat, 31-Oct 10:40 AM ET)
Catalyst watch: Election drama, jobs report, Apple and McDonald's in the earnings confessional
Seeking Alpha News (Fri, 30-Oct 3:00 PM ET)
Amgen Sets Nov. 3 Webcast for Q3 2026 Results, With a 90-Day Replay Window
Market Chameleon (Thu, 29-Oct 4:02 AM ET)
TipRanks (Thu, 29-Oct 5:40 AM ET)
AMGEN ANNOUNCES WEBCAST OF 2026 THIRD QUARTER FINANCIAL RESULTS
PRNewswire (Wed, 28-Oct 4:30 PM ET)
AMGEN ANNOUNCES 2026 FOURTH QUARTER DIVIDEND
PRNewswire (Tue, 27-Oct 6:28 PM ET)
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Amgen trades on the NASDAQ stock market under the symbol AMGN.
As of November 2, 2026, AMGN stock price declined to $465.45 with 2,553,810 million shares trading.
AMGN has a beta of 0.12, meaning it tends to be less sensitive to market movements. AMGN has a correlation of 0.00 to the broad based SPY ETF.
AMGN has a market cap of $251.64 billion. This is considered a Mega Cap stock.
Last quarter Amgen reported $10 billion in Revenue and $6.29 earnings per share. This beat revenue expectation by $629 million and exceeded earnings estimates by $.69.
In the last 3 years, AMGN traded as high as $475.65 and as low as $253.30.
The top ETF exchange traded funds that AMGN belongs to (by Net Assets): VTI, VOO, QQQ, SCHD, IVV.
AMGN has outperformed the market in the last year with a price return of +59.3% while the SPY ETF gained +11.4%. AMGN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +21.5% and +9.5%, respectively, while the SPY returned +0.9% and -1.9%, respectively.
AMGN support price is $457.14 and resistance is $474.88 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AMGN shares will trade within this expected range on the day.
